Sanofi annual net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sanofi Net Income Growth & History (SAN)
Sanofi's net income was €7.85B for fiscal 2025.
View full Sanofi company overviewSanofi annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €7.85B | €2.23B | +39.75% |
| 2024 | 2024-12-31 | €5.62B | €182.0M | +3.35% |
| 2023 | 2023-12-31 | €5.44B | −€3.05B | −35.93% |
| 2022 | 2022-12-31 | €8.48B | €2.21B | +35.12% |
| 2021 | 2021-12-31 | €6.28B | −€6.05B | −49.08% |
| 2020 | 2020-12-31 | €12.33B | €9.54B | +342.73% |
| 2019 | 2019-12-31 | €2.79B | −€1.63B | −36.85% |
| 2018 | 2018-12-31 | €4.41B | −€4.13B | −48.34% |
| 2017 | 2017-12-31 | €8.54B | €3.74B | +77.85% |
| 2016 | 2016-12-31 | €4.80B | €412.0M | +9.39% |
| 2015 | 2015-12-31 | €4.39B | — | — |
Sanofi quarterly net income
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €343.0M | −€3.60B | −91.29% |
| Q1 2026 | 2026-03-31 | €1.61B | — | — |
| Q4 2025 | 2025-12-31 | −€801.0M | — | — |
| Q3 2025 | 2025-09-30 | €2.80B | — | — |
| Q2 2025 | 2025-06-30 | €3.94B | — | — |
Sanofi net income trends
Over the last five fiscal years, Sanofi's net income decreased from €12.33B to €7.85B, a change of −€4.48B. The latest reported quarter, Q2 2026, shows €343.0M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sanofi source filings ↗Community posts
Sanofi raises annual outlook as Dupixent drives double-digit sales growth
Sanofi ($SAN-EURONEXT) increased its 2026 outlook to low-teens sales growth and mid-teens growth in business earnings per share, both at constant exchange rates. Third-quarter 2026 sales reached €14.44 billion, increasing 14.3% on that basi ...
